Angiotensin-Converting Enzyme Inhibitors May Up Lung Cancer Risk

Share this content:
Higher risk seen with ACEIs vs angiotensin receptor blockers; risk linked to duration of use
Higher risk seen with ACEIs vs angiotensin receptor blockers; risk linked to duration of use

(HealthDay News) -- The use of angiotensin-converting enzyme inhibitors (ACEIs) is associated with an increased risk for lung cancer compared with angiotensin receptor blockers, according to a study published online Oct. 24 in the BMJ.

Blánaid M. Hicks, PhD, from Jewish General Hospital in Montreal, and colleagues conducted a population-based cohort study involving 992,061 patients newly treated with antihypertensive drugs to examine whether use of ACEIs versus angiotensin receptor blockers was correlated with the risk for lung cancer.

The researchers identified 7952 incident lung cancer events during a mean follow-up of 6.4 years. Compared with the use of angiotensin receptor blockers, ACEI use was correlated with an increased risk for lung cancer (incidence rate, 1.6 vs 1.2 per 1000 person-years; hazard ratio, 1.14). With longer duration of use, hazard ratios gradually increased, with an association evident after 5 years of use and peaking after more than 10 years (hazard ratios, 1.22 and 1.31, respectively). The findings were similar for time since initiation.

"Although the magnitudes of the observed estimates are modest, these small relative effects could translate into large absolute numbers of patients at risk for lung cancer, so these findings need to be replicated in other settings," the authors write.

One author disclosed ties to the pharmaceutical industry.

References

Abstract/Full Text
Editorial

You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup